Epilepsy, Tonic-Clonic: Clinical Trials

9 trials for Epilepsy, Tonic-Clonic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting, 1 enrolling by invitation, 1 recruiting. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Completed 6, Active not recruiting 1, Enrolling by invitation 1, Recruiting 1

Follow Epilepsy, Tonic-Clonic: new trials by email Literature Review of Epilepsy, Tonic-Clonic trials Research Report on Epilepsy, Tonic-Clonic

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome
Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS)
Phase 3RecruitingFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1202025-12-222026-01-12
Clinical Trial of Vormatrigine in Adult Patients With Epilepsy
vormatrogine - Epilepsy, Tonic-Clonic, Focal Seizure
Phase 3Enrolling by invitationPraxis Precision Medicines7002025-10-272026-08-03
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure
Phase 3Active not recruitingZogenix, Inc.872022-03-082026-04-29
Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
Levetiracetam - Epilepsy, Tonic-clonic
Phase 3CompletedUCB Pharma SA662005-08-102018-11-21
Study Evaluating LAMICTAL Extended-Release Therapy Added To Current Seizure Treatments In Patients With Primary Generalized Tonic-Clonic Seizures (PGTC) Seizures
lamotrigine (LAMICTAL) extended-release, Placebo - Epilepsy, Tonic-Clonic
Phase 3CompletedGlaxoSmithKline1532004-12-012017-01-02
Monotherapy With Levetiracetam or Carbamazepine in Patients Suffering From Epilepsy.
LEVETIRACETAM - Epilepsy, Tonic-clonic
Phase 3CompletedUCB Pharma2502003-07-012013-11-26
A Study on Safety and Efficacy of Two Doses of Topiramate as Monotherapy in the Treatment of Newly Diagnosed or Recurrent Epilepsy
topiramate - Epilepsy, Seizures
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.7501999-07-012011-06-08
A Study of the Efficacy and Safety of Topiramate in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures
topiramate - Epilepsy, Seizures
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.801994-12-012011-06-08
A Study of the Efficacy and Safety of Topiramate as "Add on" Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures
topiramate - Epilepsy, Seizures
Phase 3CompletedJohnson & Johnson Pharmaceutical Research & Development, L.L.C.801994-03-012011-06-08

Narrower conditions

Epilepsy (8)  ·  Seizures (7)  ·  Alzheimer Disease (1)  ·  CDKL5 deficiency disorder (1)  ·  Dementia (1)  ·  Down Syndrome (1)  ·  Epilepsies, Partial (1)  ·  Epilepsy, Generalized (1)  ·  Spasms, Infantile (1)

Broader conditions

Brain Diseases (9)  ·  Central Nervous System Diseases (9)  ·  Nervous System Diseases (9)  ·  Epilepsy, Generalized (8)  ·  Neurologic Manifestations (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Signs and Symptoms (7)  ·  Abnormalities, Multiple (1)  ·  Chromosome Disorders (1)  ·  Congenital Abnormalities (1)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Epilepsy (1)  ·  Epileptic Syndromes (1)  ·  Genetic Diseases, Inborn (1)  ·  Intellectual Disability (1)

Interventions

Levetiracetam (3)  ·  Topiramate (3)  ·  Fenfluramine (1)  ·  Lamotrigine (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (3)  ·  Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1)  ·  GlaxoSmithKline (1)  ·  Praxis Precision Medicines (1)  ·  UCB Pharma (1)  ·  UCB Pharma SA (1)  ·  Zogenix, Inc. (1)

Countries

Germany (3)  ·  Spain (3)  ·  United States (3)  ·  Brazil (2)  ·  Italy (2)  ·  Poland (2)  ·  Argentina (1)  ·  Austria (1)  ·  Belgium (1)  ·  Chile (1)  ·  Czechia (1)  ·  Georgia (1)  ·  Hungary (1)  ·  India (1)  ·  Ireland (1)

Results publications

PMID 10227614, PMID 10768306, PMID 17283312, PMID 20937567

NIH funding

2023 (1)